Literature DB >> 22700005

QTc prolongation after regadenoson administration.

Ankur Gupta1, Steven Borer, Gary V Heller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22700005     DOI： 10.1007/s12350-012-9589-7

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  4 in total

1.  Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.

Authors:  Robert C Hendel; Timothy M Bateman; Manuel D Cerqueira; Ami E Iskandrian; Jeffrey A Leppo; Brent Blackburn; John J Mahmarian
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

2.  QT interval in right and left bundle-branch block.

Authors:  S Talbot
Journal:  Br Heart J       Date:  1973-03

3.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

4.  Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs.

Authors:  Gong Zhao; Sabrina Serpllion; John Shryock; Eric Messina; Xiaobin Xu; Manuel Ochoa; Luiz Belardinelli; Thomas H Hintze
Journal:  J Cardiovasc Pharmacol       Date:  2008-11       Impact factor: 3.105
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.